Not found to affect the activity of CYP- enzymes. Beside some adverse effect that might restrict food intake, like nausea, no potentially porphyrinogenic effects are suspected for argatroban.

Synthetic L-arginine derivative with quinolinyl-sulfonyl piperideine-carbolic acid functions. The sulfonamide functional group is not coupled to a benzamine function, and therefore argatroban does not contain the chemical sub-structure associated with other porphyrinogenic sulfonamides.

Argatroban is used for anticoagulation in patients with heparin-induced platelet deficiency, and in need of antithrombotic therapy. It is administered as an intravenous infusion. Adverse effects of possible relevance to porphyria are nausea and vomiting.

Probably not significant.

Mainly distributed to the extracellular compartment. The binding to albumin and acid glycoprotein is 20 and 34 per cent, respectively. Elimination half time is about 50 minutes. Steady state is reached after 1-3 hours of infusion. The metabolism is not fully elucidated. Three metabolites are identified generated via hydroxylation and aromatization of the methyl-quinoline ring. In vitro, Cyp3A4 and 3A5 show to generate these metabolites, but CYP-enzymes is not thought to be a significant contributor to the elimination of argatroban in vivo.